American Society of Nephrology Annual Meeting

American Society of Nephrology Annual Meeting

Source:

Bakris GL, et al. Paper SA-OR21. Presented at: ASN Kidney Week; Nov. 4-7, 2021 (virtual meeting).

November 07, 2021
1 min watch
Save

VIDEO: Finerenone induced reduction in albuminuria for patients with CKD, diabetes

Source:

Bakris GL, et al. Paper SA-OR21. Presented at: ASN Kidney Week; Nov. 4-7, 2021 (virtual meeting).

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.

Researchers presented the secondary kidney outcomes of FIGARO-DKD, a randomized, double-blind, placebo-controlled phase 3 trial, at ASN Kidney Week. They found finerenone induced a pronounced reduction in albuminuria for patients with stage 1-4 chronic kidney disease and type 2 diabetes.

“Bottom line is that there was a 23% risk reduction in doubling of creatinine. Number two, and I think more important, there was a 20% reduction in time to dialysis. So, we reduced the time to dialysis by 20% in these people that did not necessarily have advanced kidney disease. They had eGFRs in the 60s with microalbuminuria,” he said.